NASDAQ:ENVB Enveric Biosciences (ENVB) Stock Price, News & Analysis $0.51 -0.02 (-3.79%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$0.48▼$0.5250-Day Range$0.45▼$0.6052-Week Range$0.41▼$2.92Volume36,166 shsAverage Volume160,007 shsMarket Capitalization$4.53 millionP/E RatioN/ADividend YieldN/APrice Target$10.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends Get Enveric Biosciences alerts: Email Address Enveric Biosciences MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside1,871.2% Upside$10.00 Price TargetShort InterestHealthy5.29% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.98) to ($1.02) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.88 out of 5 stars 3.5 Analyst's Opinion Consensus RatingEnveric Biosciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageEnveric Biosciences has received no research coverage in the past 90 days.Read more about Enveric Biosciences' stock forecast and price target. Previous Next 4.0 Short Interest Percentage of Shares Shorted5.29% of the float of Enveric Biosciences has been sold short.Short Interest Ratio / Days to CoverEnveric Biosciences has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Enveric Biosciences has recently decreased by 80.85%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldEnveric Biosciences does not currently pay a dividend.Dividend GrowthEnveric Biosciences does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ENVB. Previous Next 0.6 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 1 news article for Enveric Biosciences this week, compared to 1 article on an average week.Search Interest3 people have searched for ENVB on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Enveric Biosciences to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Enveric Biosciences insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 1.20% of the stock of Enveric Biosciences is held by insiders.Percentage Held by InstitutionsOnly 13.82% of the stock of Enveric Biosciences is held by institutions.Read more about Enveric Biosciences' insider trading history. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Enveric Biosciences are expected to grow in the coming year, from ($1.98) to ($1.02) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Enveric Biosciences is -0.08, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Enveric Biosciences is -0.08, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioEnveric Biosciences has a P/B Ratio of 0.83. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Enveric Biosciences' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Paradigm Press Fmr CIA Advisor reveals PEACEMAKER superweaponKamala cannot get the “codes” to this superweapon. In Trump’s hands, it will restore America’s global dominance. It could also help Americans struggling under Bidenomics by potentially sending 5 military stocks SOARING. Historically, similar stocks have shot up 16,270% in just 18 months.Full details are in this announcement. About Enveric Biosciences Stock (NASDAQ:ENVB)Enveric Biosciences, Inc., a biotechnology company, engages in the development of small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders. Its lead product candidates are EB-002, an active metabolite of psilocybin, which is in preclinical development stage for the treatment of anxiety disorders; and EB-003 that is in preclinical development stage for the treatment mental health. The company also focuses on the development of cannabinoid conjugate molecules for the treatment of pain and cancer. Enveric Biosciences, Inc. is headquartered in Naples, Florida.Read More ENVB Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ENVB Stock News HeadlinesSeptember 4 at 8:05 AM | finance.yahoo.comEnveric Biosciences to Present at the H.C. Wainwright 26th Annual Global Investment ConferenceAugust 26, 2024 | nz.finance.yahoo.comEnveric Biosciences, Inc. (ENVB)September 7, 2024 | Weiss Ratings (Ad)America dodged a crisis — next time it could be much worseLegendary financial forecaster, Dr. Martin Weiss, has been warning us about it for months … He believes the next incident could lead to people seeing their bank accounts frozen.August 15, 2024 | uk.investing.comEnveric secures patent for radiation dermatitis topical productAugust 13, 2024 | finance.yahoo.comEnveric Biosciences Reports Second Quarter 2024 Financial and Corporate ResultsJuly 25, 2024 | msn.comNon-Hallucinogenic Psychedelic Treatment For Mental Health Disorders Shows Potential To Be Dosed OrallyJuly 25, 2024 | finance.yahoo.comEnveric Biosciences Announces Preclinical Results Confirming Potential of EB-003 to be Dosed OrallyJune 28, 2024 | globenewswire.comDiamond Equity Research Releases Update Note on Enveric Biosciences Inc. (NASDAQ: ENVB)September 7, 2024 | Weiss Ratings (Ad)America dodged a crisis — next time it could be much worseLegendary financial forecaster, Dr. Martin Weiss, has been warning us about it for months … He believes the next incident could lead to people seeing their bank accounts frozen.June 25, 2024 | businesswire.comEnveric Biosciences Provides Strategic Outlook and Pipeline Update, Elevating EB-003 to Lead Development CandidateMay 30, 2024 | businesswire.comEnveric Biosciences to Participate in BIO International Convention 2024May 16, 2024 | benzinga.com'Psychedelics-Inspired' Meds For Depression, Anxiety, Addiction Producer Trims Q1 Net Loss YoY, Increases Cash On HandMay 15, 2024 | msn.comEnveric Biosciences GAAP EPS of -$0.61May 15, 2024 | businesswire.comEnveric Biosciences Reports First Quarter 2024 Financial and Corporate ResultsMay 14, 2024 | msn.comMicrodosing For Depression: Psychedelics Biotech Signs $66.5M Non-Binding Deal To Out-License Novel Psilocin Prodrug CandidateMay 14, 2024 | businesswire.comEnveric Biosciences Signs $66.5 Million Non-Binding Term Sheet with MindBio Therapeutics to Out-License Novel Psilocin Prodrug Candidate for Mental Health DisordersMay 8, 2024 | msn.comCannabinoids With Chemotherapy For Breast Cancer: Psychedelics Biotech Inks $61M License Deal For Patented MethodsMay 8, 2024 | businesswire.comEnveric Biosciences Announces Signing of Non-Binding Term Sheet with Undisclosed Licensee for Exclusive License to Patented Methods of Treating Breast and Other Cancers Using CannabinoidsSee More Headlines Receive ENVB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Enveric Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/12/2024Today9/07/2024Next Earnings (Estimated)11/11/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:ENVB CUSIPN/A CIK890821 Webjaypharma.co Phone(239) 302-1707Fax732-243-9254Employees7Year FoundedN/APrice Target and Rating Average Stock Price Target$10.00 High Stock Price Target$10.00 Low Stock Price Target$10.00 Potential Upside/Downside+1,871.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($6.41) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-17,290,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-260.30% Return on Assets-164.11% Debt Debt-to-Equity RatioN/A Current Ratio8.56 Quick Ratio8.56 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.61 per share Price / Book0.83Miscellaneous Outstanding Shares8,920,000Free Float7,859,000Market Cap$4.53 million OptionableNot Optionable Beta0.73 Beginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report Key ExecutivesDr. Joseph Edward Tucker Ph.D. (Age 55)CEO & Director Comp: $450.79kMr. Kevin M. Coveney CPA (Age 60)Chief Financial Officer Comp: $385.62kDr. Peter J. Facchini Ph.D. (Age 60)Chief Innovation Officer Comp: $233.27kKey CompetitorsAptorum GroupNASDAQ:APMiBioNYSE:IBIOGalmed PharmaceuticalsNASDAQ:GLMDExicureNASDAQ:XCURSensei BiotherapeuticsNASDAQ:SNSEView All CompetitorsInsiders & InstitutionsAdvisorShares Investments LLCBought 78,214 shares on 8/8/2024Ownership: 3.988%Frank PasqualoneBought 1,000 shares on 9/15/2023Total: $2,140.00 ($2.14/share)View All Insider TransactionsView All Institutional Transactions ENVB Stock Analysis - Frequently Asked Questions How have ENVB shares performed this year? Enveric Biosciences' stock was trading at $1.30 at the beginning of 2024. Since then, ENVB shares have decreased by 61.0% and is now trading at $0.5073. View the best growth stocks for 2024 here. How were Enveric Biosciences' earnings last quarter? Enveric Biosciences, Inc. (NASDAQ:ENVB) posted its quarterly earnings results on Monday, August, 12th. The company reported ($0.25) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.55) by $0.30. When did Enveric Biosciences' stock split? Enveric Biosciences shares reverse split on Friday, July 15th 2022. The 1-50 reverse split was announced on Friday, July 15th 2022. The number of shares owned by shareholders was adjusted after the market closes on Friday, July 15th 2022. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split. Who are Enveric Biosciences' major shareholders? Top institutional investors of Enveric Biosciences include AdvisorShares Investments LLC (3.99%). View institutional ownership trends. How do I buy shares of Enveric Biosciences? Shares of ENVB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ENVB) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredTrump’s weapon lurks in abandoned AmericaUnemployment is sky-high, wages are at record lows. Addiction has overwhelmed these once thriving coal towns. ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Enveric Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Enveric Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ENVB Stock Alerts